Work

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps5087

Authors: Sumit Kumar Subudhi, Ana Aparicio, Amado J. Zurita, Bernard Doger, William Kevin Kelly, Avivit Peer, Dana E. Rathkopf, Lawrence Ivan Karsh, Jeffrey J. Tryon, Nishi Kothari, Xin Zhao, Eugene Zhu, Deborah S. Ricci, Namphuong Tran, Johann S. De Bono

Institutions: The University of Texas MD Anderson Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, Rambam Health Care Campus, Memorial Sloan Kettering Cancer Center, The Urology Center of Colorado, Janssen Research & Development (United States), Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947758134

Cites:

Cited by: 4

Related to: 10